Posted: 25 Jan 2013 Last revised: 4 Feb 2014
Date Written: January 24, 2013
Parallel trade traditionally enjoys a significant protection from European Institutions, in the belief that it fosters competition and encourages trade. However, pharmaceutical companies claim that this form of competition undermines their incentive to innovate and threatens the competitiveness of the European pharmaceutical sector. This Article analyses a) the arguments put forward in favour of and against the freedom of parallel trade of pharmaceuticals between the EU Member States and b) the case-law relating to parallel trade of pharmaceuticals developed by the EU courts and more specifically by the Court of Justice (“CJ”) (former Court Justice of the European Communities/“ECJ”)and by the General Court (“GC”) (former Court of First Instance of the European Communities/“CFI”) in the light of the EU competition law (Articles 101-102 of the TFEU).
Keywords: Competition, EU Law, Pharmaceuticals, Parallel Trade
JEL Classification: L4, K21, K33
Suggested Citation: Suggested Citation
Grigoriadis, Lazaros Grigorios, The Application of EU Competition Law in the Pharmaceutical Sector: The Case of Parallel Trade (January 24, 2013). European Business Law Review, Vol. 25, No. 1, 2014, pp. 141-201. Available at SSRN: https://ssrn.com/abstract=2206244